Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 4.30%, ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $57.68 which represents a decrease of $-0.32 or -0.55% from the prior close of $58. The stock opened at $57.65 and touched a low of ...

Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a "Buy" with strong ...

Pre-tax profits at the main Irish unit of pharma giant Bristol Myers Squibb last year declined by 42% to $3.97 billion (€3.82 ...

A big dividend yield for a few years doesn't mean much if it can't be sustained. Even though Bristol-Myers Squibb isn't generating a profit, it is generating healthy free cash flows that easily ...

Shares of Bristol Myers Squibb Co. BMY slumped 0.55% to $57.68 Friday, on what proved to be an all-around poor trading ...